Compare StocksABBV vs CPAY

AbbVie Inc. (ABBV) vs Corpay, Inc. (CPAY): Which Is the Better Buy in 2026?

As of 2026-08-03, ABBV is overvalued at $251, with a DCF intrinsic value of $178 and a margin of safety of -41%. CPAY is undervalued at $382, with an intrinsic value of $486 and a margin of safety of 21%. Of the two, CPAY has the wider margin of safety.

ABBV
AbbVie Inc.
$250.94
VS
CPAY
Corpay, Inc.
$382.11

Rewards

ABBV
  • AbbVie Inc. has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
  • Gross margin of 72.8% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • AbbVie Inc. scores 82/100 on the Economic Moat Score (Wide Moat), with reinvestment efficiency as the strongest competitive dimension.
CPAY
  • Gross margin of 79.7% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • Corpay, Inc. scores 93/100 on the Economic Moat Score (Wide Moat), with revenue predictability as the strongest competitive dimension.
  • Free cash flow has grown at a 29.1% CAGR over the past 4 years, demonstrating strong earnings power growth.

Risks

ABBV
  • Buybacks have been poorly timed — 3 out of 4 years involved repurchases at relatively expensive valuations.
  • Free cash flow has declined at a 9.8% CAGR over the past 4 years — a concerning trend.
CPAY
  • Each dollar of retained earnings has produced only $0.50 of earning power — shareholders may have been better served by dividends.
  • High leverage (2.05x net debt/equity) combined with thin interest coverage (-1.0x) poses financial risk.
  • Altman Z-Score of 1.50 places the company in the distress zone — financial patterns resemble those of companies that experienced bankruptcy.

Key Valuation Metrics

Learn more →
ABBV
CPAY
Valuation
N/A
Free Cash Flow
$2.10B
N/A
FCF Yield
8.39%
70.89
Trailing P/E
22.88
15.41
Forward P/E
12.49
Quality & Moat
27.60%
ROIC
10.91%
N/A
ROE
32.12%
72.79%
Gross Margin
79.71%
0.41
PEG Ratio
0.92
Balance Sheet Safety
N/A
Net Debt / Equity
2.05
N/A
Interest Coverage
N/A
2.06
Net Debt / EBITDA
3.11
2.76%
Dividend Yield
0.00%
ABBV: 4Ties: 1CPAY: 3
ABBVCPAY

Historical Fundamentals

Learn more →
ABBV

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

CPAY

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

$1 Retained Earnings Test

Learn more →
ABBV
N/A
Net losses over 3 years — test not applicable
Company had negative cumulative retained earnings
Σ Retained
$-19.85B
Δ Market Cap
+$118.02B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
CPAY
$2.32
created per $1 retained over 3 years
Exceptional Value Creator
Σ Retained
$3.06B
Δ Market Cap
+$7.10B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Discounted Cash Flow (DCF) Analysis

Learn more →
ABBV
40.7% Overvalued
Price is 40.7% above estimated fair value
Current Price: $250.94
Fair Value: $178.31
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
CPAY
21.3% Margin of Safety
Price is 21.3% below estimated fair value
Current Price: $382.11
Fair Value: $485.66
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued

Reverse DCF — Market-Implied Growth

Learn more →
ABBV

Requires positive FCF to compute implied growth rate.

CPAY

What growth rate is the market pricing in at $382?

+11.3%
Market-Implied Owner Earnings Growth
Standard FCF implies +4.4%

The market implies +11.3% Owner Earnings growth, above historical trends.

Standard FCF implies a demanding +4.4%, reflecting heavy growth investment.

Economic Moat Score

Learn more →
ABBV
82/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. Reinvestment Efficiency is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
CPAY
93/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. Revenue Predictability is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

Forensic Accounting

Learn more →
ABBV
-2.86
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
CPAY
-2.52
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Ownership Breakdown

Learn more →
ABBV
Insiders 0.1%Institutions 76.9%Retail & Other 23.0%
No. of Institutional Holders5,146
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
CPAY
Insiders 3.9%Institutions 102.3%
No. of Institutional Holders1,019
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

Insider Buying Activity

Learn more →
ABBV
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises
CPAY
0
Buys (3M)
1
Buys (12M)
Total value (12M): $2.52M
STULL STEVEN T
Director
$2.52M
@ $314.98 · 2025-12-12
Open market purchases · includes direct & indirect ownership · excludes option exercises

Open market purchases · includes direct & indirect ownership · excludes option exercises.

Insider Selling Activity

Learn more →
ABBV
0
Sells (3M)
5
Sells (12M)
Total value (12M): $21.79M
PURDUE DAVID RYAN
Officer
$1.22M
@ $233.56 · 2026-03-04
SIATIS PERRY C.
General Counsel
$4.38M
@ $234.39 · 2026-03-02
SIATIS PERRY C.
General Counsel
$5.15M
@ $230.00 · 2026-02-25
SALEKI-GERHARDT AZITA
Chief Operating Officer
$8.41M
@ $198.42 · 2025-08-12
DONOGHOE NICHOLAS
Officer
$2.64M
@ $198.51 · 2025-08-05
STEWART JEFFREY RYAN
Officer
$12.36M
@ $210.08 · 2025-03-31
REENTS SCOTT T.
Chief Financial Officer
$3.75M
@ $212.34 · 2025-03-14
SIATIS PERRY C.
General Counsel
$5.82M
@ $208.69 · 2025-03-03
GONZALEZ RICHARD A
Director
$20.26M
@ $205.45 · 2025-03-03
RICHMOND TIMOTHY J
Officer
$4.47M
@ $210.45 · 2025-03-03
BUCKBEE KEVIN K
Officer
$3.85M
@ $203.41 · 2025-02-26
RICHMOND TIMOTHY J
Officer
$6.07M
@ $202.90 · 2025-02-26
SIATIS PERRY C.
General Counsel
$1.14M
@ $197.90 · 2025-02-20
BUCKBEE KEVIN K
Officer
$310,032
@ $172.24 · 2024-12-16
GONZALEZ RICHARD A
Officer and Director
$12.40M
@ $186.52 · 2024-08-05
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
CPAY
4
Sells (3M)
6
Sells (12M)
Total value (12M): $34.75M
NETTO ARMANDO LINS
Officer
$24.82M
@ $352.13 · 2026-06-15
NETTO ARMANDO LINS
Officer
$1.60M
@ $351.60 · 2026-06-11
STULL STEVEN T
Director
$360,780
@ $360.78 · 2026-06-02
NETTO ARMANDO LINS
Officer
$6.13M
@ $356.18 · 2026-05-29
SLOAN JEFFREY STEVEN
Director
$1.24M
@ $343.62 · 2026-02-17
VICKERY ALISSA B
Officer
$610,067
@ $358.65 · 2026-02-10
MACCHIA RICHARD
Director
$910,683
@ $375.23 · 2025-02-10
KING ALAN
Officer
$8.13M
@ $381.97 · 2024-11-26
VICKERY ALISSA B
Officer
$2.96M
@ $370.04 · 2024-11-20
NETTO ARMANDO LINS
President
$25.50M
@ $363.42 · 2024-11-19
FARRELLY JOSEPH W.
Director
$1.12M
@ $375.18 · 2024-11-13
NETTO ARMANDO LINS
Officer
$19.70M
@ $307.33 · 2024-09-10
CLARKE RONALD F
Chief Executive Officer
$49.52M
@ $309.50 · 2024-09-03
FARRELLY JOSEPH W.
Director
$1.00M
@ $310.14 · 2024-08-29
VICKERY ALISSA B
Officer
$1.54M
@ $292.38 · 2024-08-16
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

🎭 Mr. Market's Mood

Learn more →
ABBV
FearGreed
😏Greed(61/100)

"Market is optimistic — be cautious and ensure you have a margin of safety"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
CPAY
FearGreed
😏Greed(64/100)

"Market is optimistic — be cautious and ensure you have a margin of safety"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

⚖️ Buffett Signal

Learn more →
ABBV
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Greed (61)
CPAY
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Greed (64)
View ABBV Full AnalysisView CPAY Full Analysis

Frequently Asked Questions: ABBV vs CPAY

Is AbbVie Inc. or Corpay, Inc. more undervalued in 2026?

Based on our discounted cash flow model, CPAY trades at a 21.3% margin of safety (intrinsic value $486 vs. price $382), compared to ABBV's -40.7% margin of safety (intrinsic $178 vs. $251).

Which stock has a wider economic moat, AbbVie Inc. or Corpay, Inc.?

CPAY scores 93/100 (Wide moat), while ABBV scores 82/100 (Wide moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

Is Corpay, Inc. in financial distress?

CPAY's Altman Z-Score of 1.5 places it in the Distress zone, signaling elevated bankruptcy risk. ABBV scores 2.4 (Grey zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

Which stock has higher return on invested capital, AbbVie Inc. or Corpay, Inc.?

ABBV earns 27.6% ROIC versus CPAY's 10.9%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

ABBV vs CPAY: Which Is the Better Buy in 2026? | SafetyMargin.io